Computational delivery optimization for in-vivo gene editing
Founded in Boston in 2021, Gendelivr builds the screening infrastructure that gene editing programs need to move fast on LNP delivery — without sacrificing precision.
Make LNP delivery a solved problem for gene editing programs
Delivery failure is the most common reason gene editing programs stall between target validation and IND submission. The problem is rarely the biology — it's the manual, iterative process of synthesizing and testing hundreds of LNP formulations one at a time, each taking days of bench work before a single data point emerges.
Benjamin Okafor saw this firsthand running LNP programs at two gene therapy CDMOs between 2016 and 2020. The formulation space was enormous — thousands of ionizable lipid, helper lipid, and PEG-lipid combinations — but teams were limited to sampling dozens. The rest of the space was never explored. That meant potentially better formulations were being missed, and IND timelines were stretching to 18 months because of it.
Gendelivr was founded in Boston in 2021 to replace that bench-first process with a computational screening layer: 10,000 formulations evaluated in silico in days, returning a ranked shortlist with predicted transfection efficiency, cytotoxicity margin, and synthesis protocols. We are not a CRO. We are not a reagent supplier. We are a computational platform that front-loads the formulation search so bench teams only synthesize candidates that have already survived a rigorous in silico filter.
We work with gene therapy programs that have a validated target and a CRISPR component ready to deliver — and need to reach an IND-ready formulation without the 18-month iteration cycle.
How we work
Gendelivr is a research partnership, not a reagent supplier. We embed computationally into your delivery program and deliver decision-ready output.
Program intake
We begin with your CRISPR component details: cargo size, route of administration, target tissue, regulatory timeline. That defines the formulation design space for screening.
In silico screening
Our Formulation Engine runs 10,000 LNP candidates through CGMD simulation and pKa prediction. Hit Ranking scores each by predicted hepatocyte transfection efficiency, cytotoxicity, and encapsulation stability.
IND-ready deliverables
Ranked candidate list, efficiency-toxicity scatter plot, synthesis protocols, CMC module 3 drafts, and in vitro pharmacology summary. Ready to hand to your CDMO and regulatory team.
Boston, MA — the center of gene therapy
We operate from Boston's South Station District, within reach of the Kendall Square / Longwood biotech corridor. Our team maintains active collaborations with academic groups at Harvard Medical School and the Broad Institute.
Boston's gene therapy infrastructure — from CDMOs to regulatory consultants to CROs with in vivo LNP expertise — lets us move fast from computational output to bench validation with minimal friction.
Gendelivr, Inc.300 A Street, Suite 600
Boston, MA 02210
[email protected]
+1 (617) 555-0962
Working on an in-vivo gene editing program?
Tell us about your target tissue, CRISPR component, and regulatory timeline. We'll scope what a formulation screening engagement looks like for your program.